Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D

 
• By Joseph Haas

Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.

Pedestrians wearing a protective mask walks past Pfizer Inc. headquarters on July 22, 2020 in New York City.
Pfizer will evaluate Voyager's AAV capsids as delivery mechanisms for gene therapy (Jeenah Moon/Getty Images)

More from Deals

More from Business